Opinion|Videos|November 4, 2024
Management of BsAb Toxicities by Community Oncologists Across Therapeutic Indications
Dr Graff discusses the differences and similarities in managing adverse events associated with bispecific antibodies in non-Hodgkin lymphoma compared to other therapeutic indications, such as multiple myeloma and non–small cell lung cancer.
Advertisement
Video content above is prompted by the following:
Review the recommendations on identifying, evaluating, and managing neurological toxicities.
- Workup and evaluation
- Grading of neurological toxicity
- Management of neurological toxicities
- Are there any other toxicities that are important to mention?
Please discuss the differences/similarities of bispecific antibody (BsAb) adverse event management in non-Hodgkin lymphoma vs other therapeutic indications (eg, multiple myeloma, non–small cell lung cancer).
- Is there a greater incidence of cytokine release syndrome or neurological toxicity in one disease state vs the other?
- Please address differences in BsAb protocols in different disease states.
Advertisement
Related to this article
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Arvind N. Dasari, MD, MS, reviews a year in neuroendocrine tumors marked by expanding radioligand options, improved classification, and disappointing combination therapies.
Older age, kidney disease, and prior irradiation were linked to elevated myeloid neoplasm risk after lutetium Lu 177 dotatate in a real-world NET analysis.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Claire K. Mulvey, MD, explains how patient-reported outcomes and QOL assessments reveal NEN symptom burden and help guide treatment.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Liver transplant led to durable survival in unresectable NET liver metastases; tumor burden predicted outcomes, and recurrence was common but treatable.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Advertisement
Advertisement
Trending on Targeted Onc
1
NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit
2
Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers
3
Dr Dasari on Emerging PRRT Options and New Therapeutic Targets in NETs
4
Real-World Data Reveal Risk Factors for Myeloid Neoplasm After Lutetium Lu 177 Dotatate
5